Skip to main content
WGS
NASDAQ Life Sciences

GeneDx Slashes FY26 Revenue Outlook by Over 10% After Q1 Misses Estimates

Tom Rudovsky · Reported by Reuters
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$46.057
Mkt Cap
$1.99B
52W Low
$55.17
52W High
$170.87
52W Position info
17% below low
Off High info
73% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

WGS is trading near its 52-week low of $55.17 (17% below the low).

Summary

GeneDx Holdings Corp. reported first-quarter revenue of $102.30 million and adjusted EPS of -$0.28, significantly missing analyst estimates of $112.96 million and -$0.01, respectively. More critically, the company dramatically lowered its full-year 2026 revenue guidance to $475 million-$490 million, a substantial reduction from its previous outlook of $540 million-$555 million. This news follows an 8-K filing earlier today reporting Q1 results, but this Reuters headline provides the crucial interpretation of missing estimates and the significant guidance reduction. The substantial cut in full-year guidance, representing over a 10% reduction at the midpoint, signals a material deterioration in the company's near-term financial prospects, despite a 34% year-over-year increase in test volumes. This development is highly negative and will likely trigger significant downward pressure on the stock, which is already trading near its 52-week low. Traders will be watching for analyst reactions and further commentary from management regarding the revised outlook.

At the time of this announcement, WGS was trading at $46.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $55.17 to $170.87. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

WGS - Latest Insights

WGS
Nov 10, 2026, 7:08 AM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $58.00
Real-time Price: $53.19 info
Change: -$4.81 (-8%) info
Market Cap: $1.594B info
WGS
Nov 09, 2026, 4:16 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $59.00
Real-time Price: $53.19 info
Change: -$5.81 (-10%) info
Market Cap: $1.594B info
WGS
Nov 09, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $65.65
Real-time Price: $53.19 info
Change: -$12.46 (-19%) info
Market Cap: $1.594B info
WGS
Aug 03, 2026, 4:19 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $77.01
Real-time Price: $53.19 info
Change: -$23.82 (-31%) info
Market Cap: $1.594B info
WGS
Aug 03, 2026, 4:14 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $62.47
Real-time Price: $53.19 info
Change: -$9.28 (-15%) info
Market Cap: $1.594B info